Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Guijarro, Carlos
• dc.contributor.author Civeira, Fernando
• dc.contributor.author López Miranda, José
• dc.contributor.author Masana, Luís
• dc.contributor.author Pedro-Botet, Juan Carlos
• dc.contributor.author Pintó Sala, Xavier
• dc.contributor.author Valdivielso, Pedro
• dc.contributor.author Mostaza, José María
• dc.date.accessioned 2022-05-26T06:51:39Z
• dc.date.available 2022-05-26T06:51:39Z
• dc.date.issued 2022
• dc.description.abstract Aims: During 2019 and 2020 a series of meetings over the country were carried out, with the aim of explaining the methodology and criteria for the ellaboration of the recommendations on the use of iPCSK9, published by the Spanish Society of Atherosclerosis (SEA in Spanish). At the end of the meetings, a survey was conducted among the participants, in order to describe the prescription requirements of these drugs in the Spanish regions. Methodology: Butterfly Project was developed by a scientific Committee of experts in lipids. After the ellaboration of the materials for the project, a train the trainers program was carried out, imparted by 17 experts who were the Project coordinators. Later, 16 regional workshops were performed, with the attendance of 169 medical doctors involved in the management of hipercolesterolemia. The attendants responded the survey, where they were asked different questions on the use of iPCSK9 on their clinical practice. Results: A high heterogeneity among centers regarding the requirements and difficulties for iPCSK9 prescription was revealed. Twenty one per cent of responders indicated to have low difficulties to prescribe iPCSK9 in their hospitals, whereas 78% found moderate or high difficulties. The difficulties came from burocracy- administrative aspects (18%), restrictions in the indication (41%) and both (38%). In general, the obstacles did not depend on the hospital level, neither the speciality, or the presence of lipid units, although the existance of lipid units was associated with a higher number of patients treated with iPCSK9. The factors which were associated with higher difficulty in the prescription were: the presence of an approval committee in the hospitals, the frequency in the revision of the treatment by hospital pharmacy, the temporal cadence of the prescription, the profile of patients seen and the criteria followed by the specialists for the prescription. Conclusion: The results show important diferences in the treatment with iPCSK9 in the context of clinical practice in Spain. The analysis of these results will permit to make proposals regarding future actions addressed to reach the equity in the access to iPCSK9 in Spain, with the main aim of maximizing their potential benefit according to the patients profile.
• dc.format.mimetype application/pdf
• dc.identifier.citation Guijarro C, Civeira F, López-Miranda J, Masana L, Pedro-Botet J, Pintó X, et al. Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional. Clin Investig Arterioscler. 2022 Ene-Feb; 34(1):10-8. DOI: 10.1016/j.arteri.2021.07.002
• dc.identifier.doi http://dx.doi.org/10.1016/j.arteri.2021.07.002
• dc.identifier.issn 0214-9168
• dc.identifier.uri http://hdl.handle.net/10230/53275
• dc.language.iso spa
• dc.publisher Elsevier
• dc.rights 0214-9168/© 2021 Los Autores. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Arteriosclerosis. Este es un artículo Open Access bajo la licencia CC BY (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Análisis coste-beneficio
• dc.subject.keyword Atherosclerotic cardiovascular disease
• dc.subject.keyword Costs benefit analysis
• dc.subject.keyword Dislipidemia
• dc.subject.keyword Dyslipidemia
• dc.subject.keyword Enfermedad cardiovascular aterosclerótica
• dc.subject.keyword Heterozygous familial hypercholesterolemia
• dc.subject.keyword Hipercolesterolemia familiar heterocigota
• dc.subject.keyword Hipercolesterolemia familiar homocigota
• dc.subject.keyword Homozygous familial hypercholesterolemia
• dc.subject.keyword Inhibidores de la proproteína convertasa subtilisina kexina 9
• dc.subject.keyword Inhibitors of proprotein convertase subtilisin kexin 9
• dc.title Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional
• dc.title.alternative Situation in 2020 of the requirements for the use of PCSK9 inhibitors in spain: results of a national survey
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion